Beam Therapeutics to present BEAM-101 trial data for sickle cell disease at upcoming ASTCT meetings in February 2025.
Quiver AI Summary
Beam Therapeutics Inc. announced that it will present data from the BEACON Phase 1/2 clinical trial of its investigational therapy BEAM-101 for sickle cell disease at the upcoming 2025 Tandem Meetings in Honolulu, Hawaii, scheduled for February 12-15. Previous data from seven patients demonstrated that BEAM-101 significantly increased fetal hemoglobin levels and reduced sickle hemoglobin, showing a favorable safety profile comparable to existing treatment methods. BEAM-101 is a genetically modified cell therapy involving CD34+ stem cells that are base-edited to enhance hemoglobin production. The company expects to release updated trial data in mid-2025.
Potential Positives
- Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the scientific community.
- BEAM-101 demonstrated robust and durable increases in fetal hemoglobin and reductions in sickle hemoglobin, showcasing its potential effectiveness in treating sickle cell disease.
- The safety profile of BEAM-101 aligns with established treatment protocols, which may facilitate confidence among healthcare providers and investors regarding its clinical viability.
- Beam Therapeutics' integrated platform in genetic medicine positions the company as a leader in the biotech field, potentially attracting further investment and partnerships.
Potential Negatives
- The press release highlights the presentation of preliminary data from a small sample size of seven patients, which may raise concerns about the robustness and generalizability of the results.
- There is a significant emphasis on forward-looking statements that include numerous risks and uncertainties, indicating potential challenges in achieving their development and commercialization goals.
- The company has not yet received regulatory approval for BEAM-101, and the timeline for such approval remains uncertain, which could hinder market entry and revenue generation.
FAQ
What is BEAM-101?
BEAM-101 is an investigational genetically modified cell therapy designed to treat severe sickle cell disease by increasing fetal hemoglobin production.
When will Beam present data from the BEACON trial?
Beam will present data from the BEACON Phase 1/2 clinical trial on February 12, 2025, at the Tandem Meetings in Honolulu, Hawaii.
What were the results of BEAM-101 in previous trials?
Previous trials showed BEAM-101 significantly increased fetal hemoglobin and improved markers of hemolysis with a favorable safety profile.
What does base editing technology do?
Base editing enables precise changes to DNA sequences without double-stranded breaks, allowing for targeted genetic modifications.
Who is presenting the BEAM-101 findings at the conference?
Dr. Ashish Gupta from the University of Minnesota will present the findings during the oral session on February 12, 2025.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BEAM Insider Trading Activity
$BEAM insiders have traded $BEAM stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $BEAM stock by insiders over the last 6 months:
- GIUSEPPE CIARAMELLA (President) has made 0 purchases and 2 sales selling 102,220 shares for an estimated $2,689,801.
- JOHN M. EVANS (CEO) sold 60,000 shares for an estimated $1,476,024
- CHRISTINE BELLON (Chief Legal Officer) has made 0 purchases and 2 sales selling 1,626 shares for an estimated $39,667.
- BETHANY J CAVANAGH (SVP, Finance and Treasurer) has made 0 purchases and 2 sales selling 1,406 shares for an estimated $34,353.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BEAM Hedge Fund Activity
We have seen 98 institutional investors add shares of $BEAM stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST TRUST ADVISORS LP removed 1,464,299 shares (-98.8%) from their portfolio in Q3 2024, for an estimated $35,875,325
- NIKKO ASSET MANAGEMENT AMERICAS, INC. added 1,328,414 shares (+59.7%) to their portfolio in Q3 2024, for an estimated $32,546,143
- KYNAM CAPITAL MANAGEMENT, LP added 1,302,085 shares (+inf%) to their portfolio in Q3 2024, for an estimated $31,901,082
- ARK INVESTMENT MANAGEMENT LLC removed 1,095,040 shares (-14.4%) from their portfolio in Q3 2024, for an estimated $26,828,480
- DEUTSCHE BANK AG\ removed 818,356 shares (-94.9%) from their portfolio in Q3 2024, for an estimated $20,049,722
- CITADEL ADVISORS LLC added 727,041 shares (+94.5%) to their portfolio in Q3 2024, for an estimated $17,812,504
- ARCH VENTURE MANAGEMENT, LLC removed 608,386 shares (-11.2%) from their portfolio in Q3 2024, for an estimated $14,905,457
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) --
Beam Therapeutics Inc.
(Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 12 – 15, 2025
,
in Honolulu, Hawaii.
Data from seven patients treated with investigational base-editing therapy BEAM-101 were previously
presented
at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. Treatment with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis. The safety profile of BEAM-101 was consistent with busulfan conditioning and autologous hematopoietic stem cell transplantation. Beam expects to present updated data from the BEACON trial in mid-2025.
Details for the oral presentation are as follows:
Title:
Safety and Efficacy of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) for the Treatment of Sickle Cell Disease with Severe Vaso-Occlusive Crises: Results from the Ongoing Phase 1/2 Beacon Study
Oral Session:
Session M - Gene Therapy and Editing and Study Design and Statistics
Presentation Time:
Wednesday, February 12, 2025, 3:15 p.m. HST
Presenter:
Ashish Gupta, M.D., Ph.D., University of Minnesota
About BEAM-101
BEAM-101 is an investigational genetically modified cell therapy for the treatment of severe sickle cell disease (SCD). The one-time therapy consists of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that have been base-edited in the promotor regions of the HBG1/2 genes and are administered via a hematopoietic stem cell transplant procedure. The BEAM-101 edit is designed to inhibit the transcriptional repressor BCL11A from binding to the promoter without disrupting BCL11A expression, leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal hemoglobin. HbF is the predominant hemoglobin variant during development and early life. The safety and efficacy of BEAM-101 is being evaluated in the ongoing BEACON Phase 1/2 study, an open-label, single-arm, multicenter trial in adult patients with SCD with severe vaso-occlusive crises (VOCs).
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to BEAM-101; our plans to advance our programs; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Contacts:
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Media:
Josie Butler
1AB
josie@1abmedia.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
